Global patterns of utilization of noninvasive tests for the clinical management of metabolic dysfunction–associated steatotic liver disease
Authors:
- Alina M. AllenAAAlina M. Allen
- Jeffrey V. LazarusJLJeffrey V. Lazarus
- Naim AlkhouriNANaim Alkhouri
- Mazen NoureddinMNMazen Noureddin
- Vincent Wai-Sun WongVWVincent Wai-Sun Wong
- Emmanuel A. TsochatzisETEmmanuel A. Tsochatzis
- Leyla de AvilaLALeyla de Avila
- Andrei RacilaARAndrei Racila
- Fatema NaderFNFatema Nader
- Henry E. MarkHMHenry E. Mark
- Linda HenryLHLinda Henry
- Maria StepanovaMSMaria Stepanova
Open Access
- 30 April 2025
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (5)
Abstract
Background: Noninvasive tests (NITs) are used to risk-stratify metabolic dysfunction–associated steatotic liver disease. The aim was to survey global patterns of real-world use of NITs. Methods: A 38-item survey was designed by the Global NASH Council. Providers were asked about risks for advanced fibrosis, which NITs (cutoff values) they use to risk-stratify liver disease, monitor progression, and which professional guidelines they follow. Results: A total of 321 participants from 43 countries completed the survey (54% hepatologists, 28% gastroenterologists, and 18% other). Of the respondents, 85% would risk-stratify patients with type 2 diabetes, obesity (82%), or abnormal liver enzymes (73%). Among NITs to rule out significant or advanced fibrosis, transient elastography (TE) and fibrosis-4 (FIB-4) were most used, followed by NAFLD Fibrosis Score, Enhanced Liver Fibrosis, and magnetic resonance elastography. The cutoffs for ruling out significant fibrosis varied considerably between practices and from guidelines, with only 50% using TE <8 kPa, 65% using FIB-4 <1.30 for age <65, and 41% using FIB-4 75% to monitor, and 66% would monitor (intermediate or high risk) annually. Finally, 65% follow professional guideline recommendations regarding NITs. Conclusions: In clinical practice, there is variability in NIT use and their thresholds. Additionally, there is suboptimal adherence to professional societies’ guidelines.Keywords
This publication has 40 references indexed in Scilit:
- Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver DiseaseJAMA, 2024
- Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US populationHepatology, 2023
- Age and the relative importance of liver‐related deaths in nonalcoholic fatty liver diseaseHepatology, 2022
- A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver DiseaseClinical Gastroenterology and Hepatology, 2022
- Liver Stiffness by Magnetic Resonance Elastography Predicts Future Cirrhosis, Decompensation, and Death in NAFLDClinical Gastroenterology and Hepatology, 2021
- Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver DiseaseClinical Gastroenterology and Hepatology, 2021
- The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver diseaseHepatology International, 2020
- Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLDHepatology, 2020
- Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort StudyHepatology, 2020
- Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy StudiesClinical Gastroenterology and Hepatology, 2015